VCYT on Nasdaq
VERACYTE, INC.
American medical laboratories services company based in South San Francisco2
In its 2026 annual report the company says: “We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions.”6 Its shares trade on Nasdaq under the symbol VCYT.2
$45.27 up 1.76 (4.04%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 21, 2026.
Overview
Compare with CareDx, Inc, CASTLE BIOSCIENCES INC or Caris Life Sciences (United States), or pick any stock.
- TickerVCYT on Nasdaq2
- IndustryServices-Medical Laboratories2
- HeadquartersSouth San Francisco, United States2
- Incorporated inDE4
- Business address6000 Shoreline Court, Suite 300, South San Francisco, Ca 940804
- Filer categoryLarge accelerated filer4
- Legal formCorporation2
- LEI529900ESWZRHXOW27Z372
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressc/o NATIONAL REGISTERED AGENTS, INC., 160 GREENTREE DR STE 101, 19904 Dover, United States2
- Registered withDivision of Corporations, Department of State, 41989982
See how the biggest companies compare on our leaderboards
At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions. Insights from these tests help patients avoid unnecessary procedures and interventions and accelerate time to appropriate treatment, thereby improving outcomes for patients across our global markets.6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
70.1%Gross margin7
11.2%Operating margin7
12.8%Net margin7
16.0%Revenue growth, 20257
5.1%Return on equity7
$126.6MFree cash flow7
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Testing brought in 94% of the revenue VERACYTE, INC. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Testing | $326.5M | $419.0M | $493.2M |
| Product | $15.6M | $13.7M | $14.3M |
| Biopharmaceutical And Other - Biopharmaceutical Revenue | $13.9M | $7.1M | $6.5M |
| Testing - Other | $7.8M | $11.8M | $6.2M |
| Biopharmaceutical And Other - Contract Manufacturing And Testing | $5.0M | $6.0M | $3.1M |
Regions
United States brought in 96% of the revenue VERACYTE, INC. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $334.5M | $423.5M | $496.6M |
| Outside the United States | $26.5M | $22.2M | $20.5M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development14¢$70.8M
- Other costs73¢$378.1M
- Income tax0¢$1.8M
- Profit13¢$66.4M
Out of $517.1M in revenue.7
Where each dollar of operating cash went, fiscal 2025
- Capital spending7¢$9.7M
- Kept or used elsewhere93¢$126.6M
Out of $136.3M of cash from operations.7
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $517.1M | $445.8M | $361.1M |
| Intangible asset amortization - cost of revenue | $10.7M | $11.6M | $18.5M |
| Total cost of revenue | $154.6M | $147.6M | $131.4M |
| Gross profit | $362.5M | $298.1M | $229.7M |
| Research and development | $70.8M | $69.3M | $57.3M |
| Selling and marketing | $100.2M | $95.4M | $101.5M |
| General and administrative | $110.8M | $110.6M | $86.2M |
| Impairment of assets | $20.5M | $3.4M | $68.3M |
| Total operating expenses | $304.8M | $282.0M | $315.5M |
| Income (loss) from operations | $57.8M | $16.1M | -$85.8M |
| Other income, net | $10.4M | $9.6M | $9.2M |
| Income (loss) before income taxes | $68.2M | $25.7M | -$76.6M |
| Income tax provision (benefit) | $1.8M | $1.6M | -$2.2M |
| Net income (loss) | $66.4M | $24.1M | -$74.4M |
| Basic (in USD per share) | $0.84 | $0.32 | -$1.02 |
| Diluted (in USD per share) | $0.82 | $0.31 | -$1.02 |
| Basic (in shares) | 78.6M shares | 76.5M shares | 72.6M shares |
| Diluted (in shares) | 80.6M shares | 78.2M shares | 72.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $362.6M | $239.1M | $216.5M | |
| Short-term investments | $50.3M | $50.4M | ||
| Accounts receivable | $44.7M | $46.5M | ||
| Supplies and inventory | $20.5M | $21.8M | ||
| Prepaid expenses and other current assets | $10.3M | $14.6M | ||
| Total current assets | $488.4M | $372.3M | ||
| Property, plant and equipment, net | $22.2M | $23.0M | ||
| Right-of-use assets, operating leases | $36.6M | $48.2M | ||
| Intangible assets, net | $89.1M | $102.3M | ||
| Goodwill | $767.2M | $745.8M | ||
| Restricted cash | $1.6M | $1.5M | ||
| Other assets | $902.0K | $7.0M | ||
| Total assets | $1.4B | $1.3B | ||
| Accounts payable | $4.6M | $8.6M | ||
| Accrued liabilities | $48.8M | $43.8M | ||
| Current portion of deferred revenue | $1.2M | $1.7M | ||
| Current portion of acquisition-related contingent consideration | $1.3M | $17.0M | ||
| Current portion of operating lease liabilities | $4.1M | $7.5M | ||
| Current portion of other liabilities | $0 | $19.0K | ||
| Total current liabilities | $59.9M | $78.6M | ||
| Deferred tax liability | $646.0K | $1.2M | ||
| Acquisition-related contingent consideration, net of current portion | $257.0K | $561.0K | ||
| Operating lease liabilities, net of current portion | $35.6M | $43.2M | ||
| Other liabilities | $0 | $411.0K | ||
| Total liabilities | $96.4M | $124.1M | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 125,000,000 shares authorized, 79,359,005 and 77,772,678 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $79.0K | $78.0K | ||
| Additional paid-in capital | $1.7B | $1.7B | ||
| Accumulated deficit | -$377.6M | -$444.0M | ||
| Accumulated other comprehensive loss | -$8.2M | -$36.1M | ||
| Total stockholders' equity | $1.3B | $1.2B | $1.0B | $1.1B |
| Total liabilities and stockholders' equity | $1.4B | $1.3B | ||
| Preferred stock, par value (in USD per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 5.0M shares | 5.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in USD per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 125.0M shares | 125.0M shares | ||
| Common stock, shares issued (in shares) | 79.4M shares | 77.8M shares | ||
| Common stock, shares, outstanding (in shares) | 79.4M shares | 77.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $362.6M | $239.1M | $216.5M | |
| Short-term investments | $50.3M | $50.4M | ||
| Accounts receivable | $44.7M | $46.5M | ||
| Supplies and inventory | $20.5M | $21.8M | ||
| Prepaid expenses and other current assets | $10.3M | $14.6M | ||
| Total current assets | $488.4M | $372.3M | ||
| Property, plant and equipment, net | $22.2M | $23.0M | ||
| Right-of-use assets, operating leases | $36.6M | $48.2M | ||
| Intangible assets, net | $89.1M | $102.3M | ||
| Goodwill | $767.2M | $745.8M | ||
| Restricted cash | $1.6M | $1.5M | ||
| Other assets | $902.0K | $7.0M | ||
| Total assets | $1.4B | $1.3B | ||
| Accounts payable | $4.6M | $8.6M | ||
| Accrued liabilities | $48.8M | $43.8M | ||
| Current portion of deferred revenue | $1.2M | $1.7M | ||
| Current portion of acquisition-related contingent consideration | $1.3M | $17.0M | ||
| Current portion of operating lease liabilities | $4.1M | $7.5M | ||
| Current portion of other liabilities | $0 | $19.0K | ||
| Total current liabilities | $59.9M | $78.6M | ||
| Deferred tax liability | $646.0K | $1.2M | ||
| Acquisition-related contingent consideration, net of current portion | $257.0K | $561.0K | ||
| Operating lease liabilities, net of current portion | $35.6M | $43.2M | ||
| Other liabilities | $0 | $411.0K | ||
| Total liabilities | $96.4M | $124.1M | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 125,000,000 shares authorized, 79,359,005 and 77,772,678 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $79.0K | $78.0K | ||
| Additional paid-in capital | $1.7B | $1.7B | ||
| Accumulated deficit | -$377.6M | -$444.0M | ||
| Accumulated other comprehensive loss | -$8.2M | -$36.1M | ||
| Total stockholders' equity | $1.3B | $1.2B | $1.0B | $1.1B |
| Total liabilities and stockholders' equity | $1.4B | $1.3B | ||
| Preferred stock, par value (in USD per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 5.0M shares | 5.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in USD per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 125.0M shares | 125.0M shares | ||
| Common stock, shares issued (in shares) | 79.4M shares | 77.8M shares | ||
| Common stock, shares, outstanding (in shares) | 79.4M shares | 77.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | $66.4M | $24.1M | -$74.4M |
| Depreciation and amortization | $21.4M | $23.5M | $27.2M |
| Loss on disposal of property, plant and equipment | $15.0K | $202.0K | $271.0K |
| Stock-based compensation | $43.6M | $36.2M | $33.1M |
| Deferred income taxes | -$581.0K | -$233.0K | -$3.8M |
| Non-cash lease expense | $3.0M | $5.0M | $4.2M |
| Revaluation of acquisition-related contingent consideration | -$15.3M | $2.2M | -$5.4M |
| Amortization of discount on short-term investments | -$3.3M | -$354.0K | -$468.0K |
| Impairment loss | $20.5M | $3.4M | $68.3M |
| Non-cash loss on deconsolidation of subsidiary | $6.7M | $0 | $0 |
| Effect of foreign currency on operations | -$3.8M | $2.1M | -$1.1M |
| Accounts receivable | -$708.0K | -$6.4M | $3.9M |
| Supplies and inventory | -$2.9M | -$5.9M | -$1.7M |
| Prepaid expenses and other current assets | -$2.1M | -$1.3M | -$458.0K |
| Other assets | $525.0K | -$1.2M | -$290.0K |
| Operating lease liability | -$2.5M | -$5.4M | -$4.3M |
| Accounts payable | -$1.0M | -$4.3M | -$134.0K |
| Accrued liabilities and deferred revenue | $6.3M | $3.5M | -$676.0K |
| Net cash provided by operating activities | $136.3M | $75.1M | $44.2M |
| Purchase of short-term investments | -$150.0M | -$50.0M | -$19.7M |
| Proceeds from sale of short-term investments | $0 | $0 | $39.8M |
| Proceeds from maturity of short-term investments | $153.3M | $0 | $5.0M |
| Loss on deconsolidation of subsidiary - cash | -$2.8M | $0 | $0 |
| Acquisition of C2i, net of cash acquired | $0 | $5.0M | $0 |
| Purchases of property, plant and equipment | -$9.7M | -$11.3M | -$10.0M |
| Net cash (used in) provided by investing activities | -$9.2M | -$56.3M | $15.1M |
| Payment of contingent consideration for acquisition | $0 | -$4.5M | $0 |
| Payment of taxes on vested restricted stock units | -$18.3M | -$10.6M | -$6.7M |
| Proceeds from the exercise of common stock options and employee stock purchases | $14.1M | $20.0M | $9.6M |
| Net cash (used in) provided by financing activities | -$4.2M | $4.9M | $2.8M |
| Increase in cash, cash equivalents and restricted cash | $122.9M | $23.7M | $62.2M |
| Effect of foreign currency on cash, cash equivalents and restricted cash | $719.0K | -$424.0K | $163.0K |
| Net increase in cash, cash equivalents and restricted cash | $123.6M | $23.3M | $62.3M |
| Purchases of property and equipment included in accounts payable and accrued liabilities | $2.3M | $1.2M | $966.0K |
No quarter-by-quarter statement was filed.
Corporate structure
VERACYTE, INC. sits at the top of its group. 8 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of VERACYTE, INC.
- FMR LLC Filed SCHEDULE 13G/A on VERACYTE, INC., latest Jun 5, 2026 (6 filings since May 7, 2025)
- Artisan Partners Limited Partnership Filed SCHEDULE 13G/A on VERACYTE, INC., latest May 13, 2026 (10 filings since Feb 4, 2022)
- State Street Corporation Filed SCHEDULE 13G on VERACYTE, INC., latest May 12, 2026 (4 filings since Feb 6, 2023)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on VERACYTE, INC., latest Apr 30, 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on VERACYTE, INC., latest Apr 29, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on VERACYTE, INC., latest Mar 27, 2026 (5 filings since Feb 10, 2022)
- ARK Investment Management LLC Filed SCHEDULE 13G/A on VERACYTE, INC., latest Jan 8, 2026 (10 filings since Dec 10, 2021)
- Wellington Management Company Filed SCHEDULE 13G/A on VERACYTE, INC., latest Aug 12, 2025 (6 filings since Feb 4, 2022)
- BlackRock Filed SCHEDULE 13G/A on VERACYTE, INC., latest Aug 1, 2025 (6 filings since Feb 3, 2022)
- Invesco Filed SC 13G/A on VERACYTE, INC., latest Feb 10, 2023 (2 filings since Feb 10, 2022)
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Filed SC 13G/A on VERACYTE, INC., latest Feb 9, 2023 (2 filings since Feb 10, 2022)
- Amova Asset Management Americas, Inc. Filed SC 13G/A on VERACYTE, INC., latest Feb 14, 2022
- VERACYTE, INC. South San Francisco, California, United States
- C2i Genomics Ltd Subsidiary · Israel
- Veracyte Diagnostics, LLC Subsidiary · Delaware, United States
- Veracyte Global, B.V. Subsidiary · Netherlands
- Veracyte International Corp. Subsidiary · Delaware, United States
- Veracyte Labs SD Corporation Subsidiary · Delaware, United States
- Veracyte Labs VA Corporation Subsidiary · Delaware, United States
- Veracyte SD, Inc. Subsidiary · Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What VERACYTE, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Operating-lease assets (leased space) | $36.6M7 Dec 31, 2025 | $48.2M7 Dec 31, 2024 | −24.1% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $362.6M7 Dec 31, 2025 | $239.1M7 Dec 31, 2024 | +51.7% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $767.2M7 Dec 31, 2025 | $745.8M7 Dec 31, 2024 | +2.9% |
| Intangible assets, net (excluding goodwill) | $89.1M7 Dec 31, 2025 | $102.3M7 Dec 31, 2024 | −12.9% |
| Indefinite-lived intangibles (excluding goodwill) | $13.5M11 Dec 31, 2024 | $7.3M11 Dec 31, 2023 | +84.9% |
| Finite-lived intangibles, gross | $146.7M7 Dec 31, 2025 | $139.4M7 Dec 31, 2024 | +5.2% |
| Accumulated amortization | $63.8M7 Dec 31, 2025 | $50.6M7 Dec 31, 2024 | +26.0% |
| Finite-lived intangibles, net | $82.9M7 Dec 31, 2025 | $88.8M7 Dec 31, 2024 | −6.6% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $20.5M7 Dec 31, 2025 | $21.8M7 Dec 31, 2024 | −5.5% |
| Finished goods | $07 Dec 31, 2025 | $3.9M7 Dec 31, 2024 | −100.0% |
| Supplies | $20.5M7 Dec 31, 2025 | $17.9M7 Dec 31, 2024 | +14.9% |
Properties, in its own words
We lease office and laboratory facilities in South San Francisco (approximately 65,700 square feet) and San Diego (approximately 50,900 square feet), California; and Austin, Texas (approximately 10,400 square feet). We believe our facilities are in good condition and adequate for their current use. We may expand or improve our current facilities or add additional facilities as appropriate to meet the needs of our operations.
Item 2 of the 10-K filed Feb 26, 2026.6
Leadership
Who has led VERACYTE, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
201520202025
- Chief executive officerMarc Stapley Jun 3, 2021 to now15
- Chief executive officerBonnie H. Anderson Oct 29, 2013 to May 19, 202116
- ChairBonnie H. Anderson Mar 6, 2017 to Dec 6, 202217
- PresidentTina Susan Nova Jan 13, 2022 to Mar 7, 202218
- PresidentBonnie H. Anderson Oct 29, 2013 to Jun 3, 201616
- Chief financial officerRebecca Chambers Jul 20, 2021 to now19
- Chief financial officerShelly D. Guyer Oct 29, 2013 to Mar 3, 201620
Board members and other officers (25)
- Chief Commercial Officer-CLIAJohn Leite Sep 6, 2023 to now21
- Chief Scientific & Med OfficerPhillip G. Febbo Oct 4, 2023 to now22
- VP, Chief Accounting OfficerJonathan Wygant Mar 3, 2022 to now23
- VP, Corporate ControllerBeverly Jane Alley Apr 5, 2021 to May 18, 202124
- Chief Scientific & Med OfficerGiulia C. Kennedy Mar 4, 2019 to Dec 8, 202225
- Chief Commercial OfficerJohn Walter Hanna Jr. Jul 1, 2019 to Dec 4, 202026
- Exec VP,General Coun,SecretaryJulie Brooks Jun 2, 2014 to Mar 6, 201727
- Principal Accounting OfficerDuncan Thomas Powell Jul 14, 2014 to Mar 6, 201528
- Board memberDavid Brent Shafer Sep 4, 2024 to now29
- Board memberMarc Stapley Mar 7, 2022 to now30
- Board memberEliav Barr Aug 11, 2022 to now31
- Board memberMuna Bhanji Mar 23, 2021 to now32
- Board memberJens Holstein Aug 4, 2020 to now33
- Board memberKevin K. Gordon Dec 13, 2016 to Jun 10, 202234
- Board memberRobert S. Epstein Jan 13, 2015 to now35
- Board memberTina Susan Nova Nov 16, 2015 to Jun 9, 202036
- Board memberJohn L. Bishop Dec 3, 2014 to Jul 19, 202337
- Board memberBonnie H. Anderson Oct 29, 2013 to Jun 6, 202316
- Board memberBrian G. Atwood Oct 29, 2013 to Jun 20, 201638
- Board memberFred E. Cohen Oct 29, 2013 to Oct 20, 202039
- Board memberJesse I. Treu Oct 29, 2013 to Mar 4, 201940
- Board memberKarin Eastham Oct 29, 2013 to now41
- Board memberSamuel D. Colella Oct 29, 2013 to May 21, 201442
- General counselAnnie McGuire Mar 2, 2022 to now43
- General counselJulie Brooks Mar 13, 2014 to Jul 30, 201444
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- C2i Genomics Ltd Israel5
- Veracyte Diagnostics, LLC Delaware5
- Veracyte Global, B.V. Netherlands5
- Veracyte International Corp. Delaware5
- Veracyte Labs SD Corporation Delaware5
- Veracyte Labs VA Corporation Delaware5
- Veracyte SAS France5
- Veracyte SD, Inc. Delaware5
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- CALDEROME INCDec 6, 2006 to Feb 27, 20084
Timeline
- Sep 14, 20268-K Entered a material agreement; Completed an acquisition or sale; Regulation FD disclosure45
- Jul 30, 20268-K Results of operations46
- Jun 11, 20268-K Executive or director change; Shareholder vote47
- May 5, 20268-K Results of operations48
- Mar 16, 20268-K Executive or director change49
- Feb 25, 20268-K Results of operations50
- Jan 12, 20268-K Results of operations51
- Nov 4, 20258-K Results of operations52
- Aug 6, 20258-K Results of operations53
- Jun 18, 20258-K Executive or director change; Shareholder vote54
- May 7, 20258-K Results of operations55
- Feb 24, 20258-K Results of operations56
- Jun 3, 2021New chief executive Marc Stapley becomes CEO15
- Oct 29, 2013New chief executive Bonnie H. Anderson becomes CEO16
Calendar
Coming up
- Nov 4, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported $0.38 a share, on Nov 4, 2025.57
When it reported results
- Jul 30, 2026Reported quarterly or annual results46
- May 5, 2026Reported quarterly or annual results48
- Feb 25, 2026Reported quarterly or annual results50
- Jan 12, 2026Reported quarterly or annual results51
- Nov 4, 2025Reported quarterly or annual results52
- Aug 6, 2025Reported quarterly or annual results53
- May 7, 2025Reported quarterly or annual results55
- Feb 24, 2025Reported quarterly or annual results56
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
504 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 40 major events, 277 insider forms, 55 large holders, 112 other. The latest 20:
- Sep 24, 2026144 EDGAR
- Sep 22, 20264 EDGAR
- Sep 21, 2026144 EDGAR
- Sep 16, 20264 EDGAR
- Sep 14, 2026144 EDGAR
- Sep 14, 20268-K EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 1, 2026144 EDGAR
- Jul 31, 202610-Q EDGAR
- Jul 30, 20268-K EDGAR
- Jun 22, 20264 EDGAR
The 504 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
109 open-market trades by officers, directors and large owners since October 2021: 1 buys and 108 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | Leite JohnGlobal Chief Commercial Off | Sale | 4,015 | $40.00 | $160.6K | Form 4 |
| Sep 14, 2026 | Holstein JensDirector | Sale | 5,000 | $40.95 | $204.8K | Form 4 |
| Sep 4, 2026 | McGuire AnnieEVP, General Counsel | Sale | 3,254 | $43.09 | $140.2K | Form 4 |
| Sep 4, 2026 | Chambers RebeccaChief Financial Officer | Sale | 3,652 | $43.10 | $157.4K | Form 4 |
| Sep 4, 2026 | Febbo Phillip G.Chief Scientific & Med Officer | Sale | 13,110 | $43.05 | $564.4K | Form 4 |
| Sep 1, 2026 | Bhanji MunaDirector | Sale | 1,864 | $42.97 | $80.1K | Form 4 |
| Jun 18, 2026 | EASTHAM KARINDirector | Sale | 3,729 | $52.89 | $197.2K | Form 4 |
| Jun 4, 2026 | Leite JohnGlobal Chief Commercial Off | Sale | 13,975 | $50.07 | $699.7K | Form 4 |
| Jun 4, 2026 | McGuire AnnieEVP, General Counsel | Sale | 3,176 | $49.76 | $158.0K | Form 4 |
| Jun 4, 2026 | Chambers RebeccaChief Financial Officer | Sale | 3,561 | $49.73 | $177.1K | Form 4 |
| Jun 4, 2026 | Stapley MarcChief Executive Officer | Sale | 138,051 | $50.12 | $6.9M | Form 4 |
| May 22, 2026 | Wygant JonathanVP, Chief Accounting Officer | Sale | 24,000 | $45.40 | $1.1M | Form 4 |
| May 20, 2026 | EPSTEIN ROBERT SDirector | Sale | 10,000 | $44.01 | $440.1K | Form 4 |
| May 6, 2026 | McGuire AnnieEVP, General Counsel | Sale | 10,204 | $39.02 | $398.2K | Form 4 |
| Mar 4, 2026 | Leite JohnGlobal Chief Commercial Off | Sale | 5,260 | $35.19 | $185.1K | Form 4 |
| Mar 4, 2026 | McGuire AnnieEVP, General Counsel | Sale | 6,658 | $35.55 | $236.7K | Form 4 |
| Mar 4, 2026 | Chambers RebeccaChief Financial Officer | Sale | 18,341 | $36.14 | $662.9K | Form 4 |
| Mar 4, 2026 | Stapley MarcChief Executive Officer | Sale | 45,523 | $35.98 | $1.6M | Form 4 |
| Mar 2, 2026 | Febbo Phillip G.Chief Scientific & Med Officer | Sale | 13,425 | $36.16 | $485.4K | Form 4 |
| Dec 16, 2025 | McGuire AnnieEVP, General Counsel | Sale | 10,739 | $43.14 | $463.2K | Form 4 |
All 109 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- FMR LLCSCHEDULE 13G/A, 6 filings May 7, 2025 to Jun 5, 202658
- Artisan Partners Limited PartnershipSCHEDULE 13G/A, 10 filings Feb 4, 2022 to May 13, 202659
- State Street CorporationSCHEDULE 13G, 4 filings Feb 6, 2023 to May 12, 202660
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202661
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 202662
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 27, 202663
- ARK Investment Management LLCSCHEDULE 13G/A, 10 filings Dec 10, 2021 to Jan 8, 202664
- Wellington Management CompanySCHEDULE 13G/A, 6 filings Feb 4, 2022 to Aug 12, 202565
- BlackRockSCHEDULE 13G/A, 6 filings Feb 3, 2022 to Aug 1, 202566
- InvescoSC 13G/A, 2 filings Feb 10, 2022 to Feb 10, 202367
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCSC 13G/A, 2 filings Feb 10, 2022 to Feb 9, 202368
- Amova Asset Management Americas, Inc.SC 13G/A, 1 filing Feb 14, 202269
- Sumitomo Mitsui Trust GroupSC 13G/A, 1 filing Feb 4, 202270
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Marc StapleyChief Executive Officer | 56 | $700.0K | $7.4M71 |
| 2025 | John LeiteGlobal Chief Commercial Officer | 54 | $510.3K | $3.2M71 |
| 2025 | Rebecca ChambersChief Financial Officer | 48 | $550.0K | $2.9M71 |
| 2025 | Annie McGuireGeneral Counsel and Head of Market Access | 46 | $500.0K | $2.8M71 |
| 2025 | Phillip FebboChief Scientific Officer and Chief Medical Officer | 59 | $561.0K | $2.5M71 |
| 2024 | Marc StapleyChief Executive Officer | 56 | $675.0K | $6.8M71 |
| 2024 | Rebecca ChambersChief Financial Officer | 48 | $530.4K | $3.6M71 |
| 2024 | John LeiteGlobal Chief Commercial Officer | 54 | $472.5K | $3.1M71 |
| 2024 | Annie McGuireGeneral Counsel and Head of Market Access | 46 | $470.8K | $3.1M71 |
| 2024 | Phillip FebboChief Scientific Officer and Chief Medical Officer | 59 | $550.0K | $2.8M71 |
| 2023 | Marc StapleyChief Executive Officer | 56 | $650.0K | $7.2M71 |
| 2023 | Phillip FebboChief Scientific Officer and Chief Medical Officer | 59 | $137.5K | $3.8M71 |
| 2023 | Rebecca ChambersChief Financial Officer | 48 | $510.0K | $2.8M71 |
| 2023 | Annie McGuireGeneral Counsel and Head of Market Access | 46 | $440.0K | $2.5M71 |
| 2023 | John LeiteGlobal Chief Commercial Officer | 54 | $421.1K | $1.9M71 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 13,486,437 | $792.1M | 0.0% | +313,819 |
| Fmr LLC | 7,702,746 | $452.4M | 0.0% | −61,103 |
| Artisan Partners Limited Partnership | 5,538,404 | $325.3M | 0.5% | +42,034 |
| Vanguard Portfolio Management LLC | 4,716,191 | $277.0M | 0.0% | +271,461 |
| State Street Corp | 4,698,128 | $276.0M | 0.0% | −345,462 |
| Vanguard Capital Management LLC | 3,593,922 | $211.1M | 0.0% | +61,690 |
| Dimensional Fund Advisors LP | 2,826,524 | $166.0M | 0.0% | −54,566 |
| First Trust Advisors LP | 2,507,902 | $147.3M | 0.1% | +390,856 |
| ARK Investment Management LLC | 2,295,951 | $134.8M | 0.9% | −757,867 |
| Wellington Management Group Llp | 2,274,160 | $133.6M | 0.0% | −284,125 |
| Geode Capital Management, LLC | 2,104,000 | $123.6M | 0.0% | +146,904 |
| Goldman Sachs Group Inc | 1,642,911 | $96.5M | 0.0% | +366,651 |
| Fuller & Thaler Asset Management, Inc. | 1,509,749 | $88.7M | 0.2% | +95,387 |
| William Blair Investment Management, LLC | 1,431,596 | $84.1M | 0.3% | +441,909 |
| Morgan Stanley | 1,191,790 | $70.0M | 0.0% | +393,988 |
| Bank Of America Corp /de/ | 1,102,279 | $64.7M | 0.0% | −346,618 |
| Driehaus Capital Management LLC | 1,045,826 | $61.4M | 0.4% | New |
| Northern Trust Corp | 996,154 | $58.5M | 0.0% | +66,654 |
| Charles Schwab Investment Management Inc | 939,983 | $55.2M | 0.0% | +16,410 |
| Oberweis Asset Management Inc/ | 877,734 | $51.5M | 1.1% | +37,900 |
| Legal & General Group Plc | 858,136 | $50.4M | 0.0% | −39,035 |
| Sumitomo Mitsui Trust Group, Inc. | 768,949 | $45.2M | 0.0% | −286,707 |
| Amova Asset Management Americas, Inc. | 768,949 | $45.1M | 0.6% | −276,098 |
| Point72 Asset Management, L.P. | 737,804 | $43.3M | 0.1% | +253,900 |
| Fisher Asset Management, LLC | 700,592 | $41.1M | 0.0% | −35,678 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
14 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +14.6% | Report |
| Nov 12, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Partial sale | $1,001 - $15,000 | +6.7% | Report |
| Jun 16, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +40.6% | Report |
| Oct 16, 2023 | Josh GottheimerDemocratic, House | Buy | $1,001 - $15,000 | +34.2% | Report |
| Sep 15, 2023 | Josh GottheimerDemocratic, House | Partial sale | $1,001 - $15,000 | −5.3% | Report |
| Apr 10, 2023 | Daniel S. GoldmanDemocratic, House | Partial sale | $1,001 - $15,000 | −22.5% | Report |
| Dec 23, 2020 | Gilbert Ray Cisneros, Jr.Democratic, House | Partial sale | $1,001 - $15,000 | +131.1% | Report |
| Dec 10, 2020 | Gilbert Ray Cisneros, Jr.Democratic, House | Partial sale | $1,001 - $15,000 | +131.8% | Report |
| Dec 8, 2020 | Josh GottheimerDemocratic, House | Partial sale | $1,001 - $15,000 | +134.0% | Report |
| Oct 29, 2020 | Gilbert Ray Cisneros, Jr.Democratic, House | Partial sale | $1,001 - $15,000 | +111.8% | Report |
| Jan 17, 2020 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −83.5% | Report |
| Dec 24, 2019 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −88.5% | Report |
| Dec 12, 2019 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −86.4% | Report |
| Dec 6, 2019 | Josh GottheimerDemocratic, House | Buy | $1,001 - $15,000 | −91.1% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How VERACYTE, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARVERACYTE, INC.1
- CIK0001384101
- Employer ID (EIN)20-54553986
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company6
- Incorporated inDelaware6
- Fiscal year endsDecember 311
- Industry code (SIC)8071 Services-Medical Laboratories1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address6000 Shoreline Court, Suite 300, South San Francisco, CA 940801
- Phone(650) 243-63001
- Shares outstanding80,390,731 as of Jul 27, 202613
- Public float$1.7B as of Jun 30, 20256
- AuditorErnst & Young LLP, San Diego, California PCAOB ID 42; it also attests to the company’s internal control over financial reporting6
- On EDGAR sinceDec 6, 20061
- Filings1,170 in all: 4 (571), 8-K (145), 144 (74), SC 13G/A (58), 3 (45), 10-Q (39), SC 13G (24), SCHEDULE 13G/A (19)1
All 47 form types
CORRESP (17), S-8 (16), UPLOAD (14), 10-K (13), DEF 14A (13), DEFA14A (12), S-8 POS (10), 424B5 (9), 424B3 (7), 8-K/A (7), SCHEDULE 13G (7), 425 (6), ARS (6), EFFECT (6), CT ORDER (5), 4/A (4), 424B7 (4), S-1/A (4), S-3 (4), SEC STAFF LETTER (4), REGDEX/A (3), S-3ASR (3), 10-Q/A (2), D (2), DRS/A (2), POS AM (2), 10-K/A (1), 3/A (1), 424B4 (1), 5 (1), 8-A12B (1), CERTNAS (1), DRS (1), FWP (1), PRE 14A (1), REGDEX (1), RW (1), S-1 (1), S-1MEF (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Jul 31, 2026
Proxy statement (DEF 14A) Apr 22, 2026
Latest 8-K (8-K) Sep 14, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value, $0.001 per share | VCYT | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).6
Risk factors and legal proceedings
The risks VERACYTE, INC. names in Item 1A of its 10-K filed Feb 26, 2026: 57 risks under these headings, as written.6
- Risks Related to Our Business
- Risks Related to Being a Public Company
- Risks Related to Our Common Stock
- Our financial results currently depend mainly on sales of our Decipher Prostate and Afirma laboratory developed tests (LDTs), and we may not generate sufficient revenue from these and our other diagnostic tests to grow our business.
- If we are unable to grow sales of our tests or products, or we are unable to launch or commercialize our new tests or products, our business may suffer.
- We have incurred losses in the past, we could incur net losses in the future and we may not sustain our level of profitability in the future.
- We depend on a few payers for a significant portion of our revenue; if one or more significant payers stops providing reimbursement or decreases the amount of reimbursement for our tests, our revenue could decline.
- If payers do not provide reimbursement, rescind or modify their reimbursement policies, delay payments for our tests, recoup past payments, or if we are unable to successfully negotiate additional reimbursement contracts, our commercial success could be compromised.
- We may experience limits on our revenue if physicians decide not to order our tests.
- We may experience limits on our revenue if patients decide not to use our tests as a result of increased costs, fees or changing payer policies.
- If we fail to comply with federal and state licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.
- We have engaged, and may continue to engage, in acquisitions, dispositions or other strategic transactions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources. If our general strategy of seeking
The other 48 risks
- incremental growth through acquisitions and collaborations is not successful, or if we do not successfully integrate companies or assets that we acquire into our business, our prospects and financial condition may suffer.
- We must successfully integrate our acquired businesses, such as C2i, to realize the strategic or financial goals that we currently anticipate.
- Our future success and international growth depend, in part, on our ability to adapt, manufacture and distribute our tests as IVD tests.
- If we do not manage inventory in an effective and efficient manner, it could adversely affect our results of operations.
- We rely on sole suppliers for some of the reagents, equipment and other materials used to perform our tests, as well as certain sole source providers for kit components, instruments and associated services. We may not be able to find replacements or transition to alternative suppliers or service providers, which may materially impact our ability to generate revenue.
- We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.
- If we are unable to support demand for our tests, products or services, our business could suffer.
- Changes in healthcare policy, including legislation reforming the U.S. healthcare system, recent U.S. judicial decisions and potential changes in the regulatory environment, may have a material adverse effect on our financial condition and operations.
- Because of Medicare billing rules, we may not receive reimbursement for all tests provided to Medicare patients.
- If the FDA or foreign authorities regulate those of our tests that they do not currently regulate, we could incur substantial costs and delays associated with trying to obtain premarket clearance, approval or certification.
- Obtaining marketing authorization or certification by the FDA and foreign regulatory authorities or notifying regulatory bodies for our diagnostic tests will take significant time and require significant research, development and clinical study expenditures and ultimately may not succeed.
- If we are unable to obtain marketing authorizations or certifications, approvals, clearances or certifications to market Prosigna or our other IVD assays or if regulatory limitations are placed on our diagnostic kit products, our business and growth will be harmed.
- We are subject to ongoing and increasingly extensive regulatory requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business.
- If we are unable to compete successfully, we may be unable to increase or sustain our revenue and profitability.
- We depend on our senior management team, and the loss of one or more of our executive officers, or any inability to attract and retain highly skilled employees and other key personnel in our highly competitive industry, could adversely affect our business.
- Billing for our diagnostic tests is complex, and we must dedicate substantial time and resources to the billing process in order to collect cash and be paid.
- We rely on third-party providers to transmit claims to payers, and any delay in transmitting claims could have an adverse effect on our revenue.
- If our internal sales force is less successful than anticipated, our business expansion plans could suffer and our ability to generate revenue could be diminished.
- Developing, commercializing and gaining reimbursement for new products involves a lengthy and complex process, and if we do not achieve our projected development, commercialization and reimbursement goals in the timeframes we announce and expect, our business may suffer, and our stock price may decline.
- If we are unable to develop products to keep pace with rapid technological, medical and scientific change, our operating results and competitive position could be harmed.
- Complying with numerous statutes and regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.
- If we use hazardous materials in a manner that causes contamination, infection or injury, we could be liable for resulting damages.
- Aspects of our international business expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.
- We have operations located in Israel, and conflict in the Middle East and any additional escalations of hostilities may cause interruption or suspension of this site without warning, or otherwise negatively impact the global economy or our business.
- Our reliance on distributors for sales of our products outside of the United States, and on clinical laboratories for delivery of Prosigna testing services, could limit or prevent us from selling our products and impact our revenue.
- Errors or defects in our products or services could harm our reputation, decrease market acceptance of our products or services or expose us to product liability claims, and we could face substantial liabilities that exceed our resources.
- Issues relating to the use of AI and machine learning in our offerings could adversely affect our business and operating results.
- Security breaches, loss of data and other disruptions to our or our third-party service providers' data systems could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.
- Risks associated with data privacy issues, including evolving laws, regulations and associated compliance efforts, may adversely impact our business and financial results.
- If we are unable to protect our intellectual property effectively, our business may be harmed.
- If we are unable to enforce or defend our intellectual property effectively, our business may be harmed.
- If we cannot license or maintain rights to use technologies on reasonable terms, our business may suffer.
- We may be involved in litigation related to third party intellectual property, which may be time-intensive and costly and may adversely affect our business, operating results or financial condition.
- Our ability to use our net operating loss carryforwards may be limited and may result in increased future tax liability to us.
- If we are unable to maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.
- Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid.
- Anti-takeover provisions in our charter documents and under Delaware law could discourage, delay or prevent a change in control and may affect the trading price of our common stock.
- We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future.
- Our quarterly operating results may fluctuate significantly or may fall below our guidance or the expectations of investors or securities analysts for various reasons, including in response to the way we recognize revenue, our level of profitability and/or the amount of cash we generate, which may cause our stock price to fluctuate or decline.
- General Risk Factors
- Our operating results may be adversely affected by unfavorable macroeconomic and market conditions.
- Our business and the operations of our laboratories and manufacturing sites are subject to the risk of disruptions caused by pandemics, political events, war, terrorism, earthquakes, fire, power outages, severe weather, floods, and other catastrophic events.
- We are exposed to risks associated with transactions denominated in foreign currency.
- We may be unable to raise additional capital on acceptable terms in the future, which could limit our ability to develop and commercialize new solutions and technologies and expand our operations, organically or inorganically.
- Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of amounts that have been accrued.
- Impairment in the value of our goodwill or other intangible assets could have a material adverse effect on our operating results and financial condition.
- Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported operating results.
- Our consolidated financial statements are subject to change and if our estimates or judgments relating to our critical accounting policies prove to be incorrect, our operating results could be adversely affected.
- Investors’ expectations of our performance relating to environmental, social and governance factors may impose additional costs and expose us to new risks.
Legal proceedings
We are not currently a party to any material legal proceedings. We may from time to time become involved in legal proceedings arising in the ordinary course of business.
The opening of Item 3, Legal Proceedings.6
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARVERACYTE, INC. filings on SEC EDGAR
- 2
- 3Yahoo FinanceVCYT quote
- 4SEC EDGARVERACYTE, INC. filings on SEC EDGAR
- 5
- 6
- 7SEC EDGARVERACYTE, INC. 10-K for fiscal 2025
- 8SEC EDGARVERACYTE, INC. 10-K for fiscal 2019
- 9SEC EDGARVERACYTE, INC. 10-K for fiscal 2020
- 10SEC EDGARVERACYTE, INC. 10-K for fiscal 2021
- 11SEC EDGARVERACYTE, INC. 10-K for fiscal 2022
- 12SEC EDGARVERACYTE, INC. 10-Q for fiscal 2026
- 13SEC EDGARVERACYTE, INC. 10-Q for fiscal 2026
- 14SEC EDGARVERACYTE, INC. 10-K for fiscal 2019
- 15
- 16
- 17SEC EDGARBonnie H. Anderson, Chair
- 18SEC EDGARTina Susan Nova, President
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29SEC EDGARDavid Brent Shafer, Board member
- 30SEC EDGARMarc Stapley, Board member
- 31SEC EDGAREliav Barr, Board member
- 32SEC EDGARMuna Bhanji, Board member
- 33SEC EDGARJens Holstein, Board member
- 34SEC EDGARKevin K. Gordon, Board member
- 35SEC EDGARRobert S. Epstein, Board member
- 36SEC EDGARTina Susan Nova, Board member
- 37SEC EDGARJohn L. Bishop, Board member
- 38SEC EDGARBrian G. Atwood, Board member
- 39SEC EDGARFred E. Cohen, Board member
- 40SEC EDGARJesse I. Treu, Board member
- 41SEC EDGARKarin Eastham, Board member
- 42SEC EDGARSamuel D. Colella, Board member
- 43SEC EDGARAnnie McGuire, General counsel
- 44SEC EDGARJulie Brooks, General counsel
- 45
- 46SEC EDGARResults of operations
- 47
- 48SEC EDGARResults of operations
- 49SEC EDGARExecutive or director change
- 50SEC EDGARResults of operations
- 51SEC EDGARResults of operations
- 52SEC EDGARResults of operations
- 53SEC EDGARResults of operations
- 54
- 55SEC EDGARResults of operations
- 56SEC EDGARResults of operations
- 57NasdaqNasdaq calendar
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67SEC EDGARInvesco SC 13G/A on VERACYTE, INC.
- 68
- 69
- 70
- 71